Compare ADCT & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADCT | NKLR |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Switzerland | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 500.6M |
| IPO Year | 2019 | N/A |
| Metric | ADCT | NKLR |
|---|---|---|
| Price | $1.13 | $4.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.75 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 3.3M | 287.9K |
| Earning Date | 05-04-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $66.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $0.78 | $3.73 |
| 52 Week High | $4.98 | $12.43 |
| Indicator | ADCT | NKLR |
|---|---|---|
| Relative Strength Index (RSI) | 27.44 | 43.07 |
| Support Level | $0.78 | $3.94 |
| Resistance Level | $1.17 | $5.25 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 77.38 | 42.40 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.